Goldman Sachs Group Inc Argenx Se Call Options Transaction History

Goldman Sachs Group Inc

  • $605 Billion
  • Q3 2024

Call Options

4 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q1 2024

May 15, 2024
BUY
$356.95 - $413.29 $3.14 Million - $3.64 Million
8,800 Added 733.33%
10,000 $3.94 Million
Q4 2023

Feb 13, 2024
BUY
$338.91 - $506.01 $406,692 - $607,212
1,200 New
1,200 $456,000
Q3 2022

May 14, 2024
BUY
$343.2 - $395.75 $2.51 Million - $2.89 Million
7,300 Added 608.33%
8,500 $3 Million
Q3 2022

Nov 10, 2022
BUY
$343.2 - $395.75 $2.92 Million - $3.36 Million
8,500 New
8,500 $3 Million

Others Institutions Holding ARGX

# of Institutions
405
Shares Held
30.8M
Call Options Held
376K
Put Options Held
489K
View Full List

About ARGENX SE

ARGX Quotes by TradingView
  • Ticker ARGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,323,800
  • Market Cap $35.4B
  • Description
  • argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...
More about ARGX
Track This Portfolio

Track Goldman Sachs Group Inc Portfolio

Follow Goldman Sachs Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email